In detail, patients with ADC harboring anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), rearranged during transfection proto-oncogene gene (RET) and neurotrophin kinase (NTRK) gene rearrangements can benefit from a treatment with tyrosine kinase inhibitors (TKIs), so an efficient and valued molecular testing is mandatory [2,3]. Here, RET is linked to AIDS dementia complex.